Clinical Trial Update: Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating maintenance low-dose azacitidine after T cell–depleted allogeneic stem cell transplantation in high-risk myelodysplastic syndromes and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Myelodysplastic Syndromes (MDS), Acute Myelogenous Leukemia (AML) | Phase 2 | Status: COMPLETED | Results posted: 2024-05-22